UNIFI Long-Term Extension Shows Safety, Efficacy of Ustekinumab for Ulcerative Colitis Through 4 Years

Results confirmed the long-term efficacy of ustekinumab maintenance in patients with ulcerative colitis, demonstrating consistent rates of symptomatic remission and endoscopic improvement with no new safety signals.

Related Keywords

Waqqas Afif ,Media Center ,Drug Administration ,Mcgill University ,Inflammatory Bowel Disease Questionnaire ,Ulcerative Colitis Through ,Final Results ,Severely Active Ulcerative ,Maintenance Ustekinumab ,Ulcerative Colitis ,Bustekinumab ,Unifi ,Interleukin 23 ,Il 23 ,Il 12 ,Inflammatory Bowel Disease ,Ibd ,Crohn X27s Disease ,Stelara ,